

bonding on July 13, 2007 and July 20, 2007.

Having examined the record in this investigation, including the submissions on review and responses thereto, the Commission has determined that there is a violation of section 337 with respect to claim 7 of the '957 patent; claims 18, 81, 93, 149, and 164 of the '439 patent; claims 83 and 84 of the '377 patent; claims 19 and 20 of the '148 patent; claim 1 of the '401 patent; claims 1, 2, 3, and 9 of the '917 patent; claims 1, 31, and 34 of the '902 patent; claims 1, 10, and 14 of the '422 patent; claim 1 of the '053 patent; and claim 21 of the '397 patent.

The Commission has also made determinations on the issues of remedy, the public interest, and bonding, as well as relief against defaulting respondents. The Commission determined that the appropriate form of relief in this investigation is a general exclusion order, limited exclusion order, and cease and desist orders.

The general exclusion order prohibits the unlicensed entry of ink cartridges for consumption covered by one or more of claim 7 the '957 patent; claims 18, 81, 93, 149, and 164 of the '439 patent; claims 83 and 84 of the '377 patent; claims 19 and 20 of the '148 patent; claim 1 of the '401 patent; claims 1, 2, 3, and 9 of the '917 patent; claims 1, 31, and 34 of the '902 patent; claims 1, 10, and 14 of the '422 patent; claim 1 of the '053 patent; and claim 21 of the '397 patent.

The limited exclusion order prohibits the unlicensed entry for consumption of certain ink cartridges that are covered by one or more of claim 165 of the '439 patent and claims 29, 31, 34, and 38 of the '472 patent that are manufactured abroad by or on behalf of, or imported by or on behalf of defaulting respondents Glory South Software Mfg., Butterfly Image Corp., Mipo International ("Mipo"), Mipo America Ltd. ("Mipo America"), AcuJet USA, Tully Imaging Supplies, Ltd. ("Tully"), Wellink Trading Co., Ltd. ("Wellink"), and Ribbon Tree (Macao) Trading Co. ("Ribbon Tree Macao") or any of their affiliated companies, parents, subsidiaries, or other related business entities, or their successors or assigns. The limited exclusion order also prohibits the unlicensed entry for consumption of certain ink cartridges that are covered by one or more of claims 45, 53, and 54 of the '397 patent that are manufactured abroad by or on behalf of, or imported by or on behalf of Mipo, Mipo America, Tully, Wellink, and Ribbon Tree Macao or any of their affiliated companies, parents,

subsidiaries, or other related business entities, or their successors or assigns.

The Commission has also determined to issue cease and desist orders covering claim 7 of the '957 patent; claims 18, 81, 93, 149, and 164 of the '439 patent; claims 83 and 84 of the '377 patent; claims 19 and 20 of the '148 patent; claim 1 of the '401 patent; claims 1, 2, 3 and 9 of the '917 patent; claims 1, 31 and 34 of the '902 patent; claims 1, 10 and 14 of the '422 patent; claim 1 of the '053 patent; and claim 21 of the '397 patent and directed to domestic respondents Ninestar U.S., Town Sky, Dataproducts, and MMC.

The Commission has further determined to issue cease and desist orders covering claim 7 of the '957 patent; claims 18, 81, 93, 149, 164, and 165 of the '439 patent; claims 83 and 84 of the '377 patent; claims 19 and 20 of the '148 patent; claims 29, 31, 34, and 38 of the '472 patent; claim 1 of the '401 patent; claims 1, 2, 3 and 9 of the '917 patent; claims 1, 31 and 34 of the '902 patent; claims 1, 10 and 14 of the '422 patent; claim 1 of the '053 patent; and claims 21, 45, 53, and 54 of the '397 patent (Mipo America only) and directed to defaulting domestic respondents Glory South Manufacturing, Mipo America, and AcuJet U.S.A.

The Commission has determined that the public interest factors enumerated in 19 U.S.C. § 1337(d), (f), and (g) do not preclude issuance of the aforementioned remedial orders, and that the bond during the Presidential period of review shall be set at \$13.60 per cartridge for covered ink cartridges.

The authority for the Commission's determinations is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in sections 210.45–210.51 of the Commission's Rules of Practice and Procedure (19 CFR 210.45–210.51).

By order of the Commission.

Issued: October 19, 2007.

**Marilyn R. Abbott,**

*Secretary to the Commission.*

[FR Doc. E7–20983 Filed 10–24–07; 8:45 am]

**BILLING CODE 7020–02–P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Importer of Controlled Substances; Notice of Application**

Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this section to a bulk manufacturer of a controlled

substance in schedule I or II and prior to issuing a registration under 21 U.S.C. 952(a)(2) authorizing the importation of such substances, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with 21 CFR 1301.34(a), this is notice that on April 13, 2007, Research Triangle Institute, Kenneth H. Davis Jr., Hermann Building East Institute Drive, P.O. Box 12194, Research Triangle Park, North Carolina 27709, made application by renewal to the Drug Enforcement Administration (DEA) for registration as an importer of the basic classes of controlled substances listed in schedule I and II:

Drug	Schedule
1-(1-Phenylcyclohexyl)pyrrolidine (7458).	I
1-[1-(2-Thienyl)cyclohexyl]piperidine (7470).	I
1-[1-(2-Thienyl)cyclohexyl]pyrrolidine (7473).	I
1-Methyl-4-phenyl-4-propionoxypiperidine (9661).	I
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine (9663).	I
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (7348).	I
2,5-Dimethoxy-4-ethylamphetamine (7399).	I
2,5-Dimethoxyamphetamine (7396).	I
3,4,5-Trimethoxyamphetamine (7390).	I
3,4-Methylenedioxyamphetamine (7400).	I
3,4-Methylenedioxymethamphetamine (7405).	I
3,4-Methylenedioxy-N-ethylamphetamine (7404).	I
3-Methylfentanyl (9813) .....	I
3-Methylthiofentanyl (9833) .....	I
4-Bromo-2,5-dimethoxyamphetamine (7391).	I
4-Bromo-2,5-dimethoxyphenethylamine (7392).	I
4-Methyl-2,5-dimethoxyamphetamine (7395).	I
4-Methylaminorex (cis isomer) (1590).	I
4-Methoxyamphetamine (7411) ...	I
5-Methoxy-3,4-methylenedioxyamphetamine (7401).	I
5-Methoxy-N,N-diisopropyltryptamine (7439).	I
Acetorphine (9319) .....	I
Acetyl-alpha-methylfentanyl (9815).	I
Acetyldihydrocodeine (9051) .....	I
Acetylmethadol (9601) .....	I
Allylprodine (9602) .....	I
Alphacetylmethadol except levo-alpha-cetylmethadol (9603).	I

Drug	Schedule	Drug	Schedule	Drug	Schedule
Alpha-ethyltryptamine (7249) .....	I	N-Hydroxy-3,4-	I	Nabilone (7379) .....	II
Alphameprodine (9604) .....	I	methylenedioxyamphetamine		Opium, raw (9600) .....	II
Alphamethadol (9605) .....	I	(7402).		Opium extracts (9610) .....	II
Alpha-methylfentanyl (9814) .....	I	Nicocodeine (9309) .....	I	Opium fluid extract (9620) .....	II
Alpha-methylthiofentanyl (9832) .....	I	Nicomorphine (9312) .....	I	Opium tincture(9630) .....	II
Alpha-methyltryptamine (7432) ....	I	N-Methyl-3-piperidyl benzilate	I	Opium, granulated (9640) .....	II
Aminorex (1585) .....	I	(7484).		Oxycodone (9143) .....	II
Benzethidine (9606) .....	I	Noracymethadol (9633) .....	I	Oxymorphone (9652) .....	II
Benzylmorphine (9052) .....	I	Norlevorphanol (9634) .....	I	Pentobarbital (2270) .....	II
Betacetylmethadol (9607) .....	I	Normethadone (9635) .....	I	Phenazocine (9715) .....	II
Beta-hydroxy-3-methylfentanyl	I	Normorphine (9313) .....	I	Phencyclidine (7471) .....	II
(9831).		Norpipanone (9636) .....	I	Phenmetrazine (1631) .....	II
Beta-hydroxyfentanyl (9830) .....	I	Para-Fluorofentanyl (9812) .....	I	Phenylacetone (8501) .....	II
Betameprodine (9608) .....	I	Parahexyl (7374) .....	I	Piminodine (9730) .....	II
Betamethadol (9609) .....	I	Peyote (7415) .....	I	Powdered opium (9639) .....	II
Betaprodine (9611) .....	I	Phenadoxone (9637) .....	I	Racemethorphan (9732) .....	II
Bufotenine (7433) .....	I	Phenampromide (9638) .....	I	Racemorphan (9733) .....	II
Cathinone (1235) .....	I	Phenomorphane (9647) .....	I	Remifentanyl (9739) .....	II
Clonitazene (9612) .....	I	Phenoperidine (9641) .....	I	Secobarbital (2315) .....	II
Codeine methylbromide (9070) ....	I	Pholcodine (9314) .....	I	Sufentanil (9740) .....	II
Codeine-N-Oxide (9053) .....	I	Piritramide (9642) .....	I	Thebaine (9333) .....	II
Cyprenorphine (9054) .....	I	Proheptazine (9643) .....	I		
Desomorphine (9055) .....	I	Properidine (9644) .....	I		
Dextromoramide (9613) .....	I	Propiram (9649) .....	I		
Diampromide (9615) .....	I	Psilocybin (7437) .....	I		
Diethylthiambutene (9616) .....	I	Psilocyn (7438) .....	I		
Diethyltryptamine (7434) .....	I	Racemoramide (9645) .....	I		
Difenoxin (9168) .....	I	Tetrahydrocannabinols (7370) ....	I		
Dihydromorphine (9145) .....	I	Thebacon (9315) .....	I		
Dimenoxadol (9617) .....	I	Thiofentanyl (9835) .....	I		
Dimepheptanol (9618) .....	I	Thiophene analog of	I		
Dimethylthiambutene (9619) .....	I	phencyclidine (7470).			
Dimethyltryptamine (7435) .....	I	Tilidine (9750) .....	I		
Dioxaphetyl butyrate (9621) .....	I	Trimeperidine (9646) .....	I		
Dipipanone (9622) .....	I	1-Phenylcyclohexylamine (7460)	II		
Drotebanol (9335) .....	I	1-	II		
Ethylmethylthiambutene (9623) ....	I	Piperidinocyclohexanecarbonitrile			
Etonitazene (9624) .....	I	(8603).			
Etorphine except HCl (9056) .....	I	Alfentanil (9737) .....	II		
Etoxadine (9625) .....	I	Alphaprodine (9010) .....	II		
Fenethylline (1503) .....	I	Amobarbital (2125) .....	II		
Furethidine (9626) .....	I	Amphetamine (1100) .....	II		
Gamma Hydroxybutyric Acid	I	Anileridine (9020) .....	II		
(2010).		Bezitramide (9800) .....	II		
Heroin (9200) .....	I	Carfentanil (9743) .....	II		
Hydromorphanol (9301) .....	I	Codeine (9050) .....	II		
Hydroxypethidine (9627) .....	I	Dextropropoxyphene, bulk (non-	II		
Ibogaine (7260) .....	I	dosage forms) (9273).			
Ketobemidone (9628) .....	I	Dihydrocodeine (9120) .....	II		
Levomoramide (9629) .....	I	Dihydroetorphine (9334) .....	II		
Levophenacetylmorphan (9631) .....	I	Diphenoxylate (9170) .....	II		
Lysergic acid diethylamide (7315)	I	Ethylmorphine (9190) .....	II		
Marihuana (7360) .....	I	Etorphine Hcl (9059) .....	II		
Mecloqualone (2572) .....	I	Fentanyl (9801) .....	II		
Mescaline (7381) .....	I	Glutethimide (2550) .....	II		
Methaqualone (2565) .....	I	Hydrocodone (9193) .....	II		
Methcathinone (1237) .....	I	Hydromorphone (9150) .....	II		
Methyldesorphine (9302) .....	I	Isomethadone (9226) .....	II		
Methyl dihydromorphine (9304) .....	I	Levo-alphaacetylmethadol (9648) ..	II		
Morpheridine (9632) .....	I	Levomethorphan (9210) .....	II		
Morphine methylbromide (9305) ..	I	Levorphanol (9220) .....	II		
Morphine methylsulfonate (9306)	I	Lisdexamfetamine (1205) .....	II		
Morphine-N-Oxide (9307) .....	I	Meperidine (9230) .....	II		
Myrophine (9308) .....	I	Meperidine intermediate-A (9232)	II		
N,N-Dimethylamphetamine (1480)	I	Meperidine intermediate-B (9233)	II		
N-[1-(2-thienyl)methyl-4-piperidyl]-	I	Meperidine intermediate-C (9234)	II		
N-phenylpropanamide (9834).		Metazocine (9240) .....	II		
N-[1-benzyl-4-piperidyl]-N-	I	Methadone (9250) .....	II		
phenylpropanamide (9818).		Methadone intermediate (9254) ...	II		
N-Benzylpiperazine (7493) .....	I	Methamphetamine (1105) .....	II		
N-Ethyl-3-piperidyl benzilate	I	Methylphenidate (1724) .....	II		
(7482).		Metopon (9260) .....	II		
N-Ethylamphetamine (1475) .....	I	Moramide intermediate (9802) ....	II		
N-Ethyl-1-phenylcyclohexylamine	I	Morphine (9300) .....	II		
(7455).					

The company plans to import small quantities of the listed controlled substances for the National Institute of Drug Abuse (NIDA) for research activities.

Any manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47.

Any such comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537; or any being sent via express mail should be sent to, Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than November 26, 2007.

This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the **Federal Register** on September 23, 1975, (40 FR 43745-46), all applicants for registration to import a basic class of any controlled substances in Schedule I or II are and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.

Dated: October 19, 2007.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of  
Division Control, Drug Enforcement  
Administration.*

[FR Doc. E7-21009 Filed 10-24-07; 8:45 am]

**BILLING CODE 4410-09-P**

## NATIONAL COUNCIL ON DISABILITY

### Cultural Diversity Advisory Committee Meeting (Teleconference)

**AGENCY:** National Council on Disability (NCD). Pursuant to the Federal Advisory Committee Act, Public Law 92-463, NCD gives notice that the Cultural Diversity Advisory Committee will hold a meeting on the date and time noted below. The Committee will meet by conference call.

**Date and Time:** Thursday, November 15, 2007, 2 p.m. Eastern Standard Time.

**Place:** National Council on Disability, 1331 F Street, NW., Suite 850, Washington, DC 20004.

**Status:** All parts of this conference call will be open to the public. People interested in participating on this call should contact the appropriate staff member listed below. Due to limited resources, only a few telephone lines will be available for the conference call.

**Agenda:** Roll call, announcements, reports, new business, adjournment. A detailed agenda will be posted 10 days before each meeting at <http://www.ncd.gov/newsroom/advisory/cultural/cultural.htm>.

**Contact Person for More Information:** To obtain information on the meeting, including the call-in number, please contact Mark Seifarth or Stacey Brown, NCD, 1331 F Street NW., Suite 850, Washington, DC 20004, 202-272-2004 (voice), 202-272-2074 (TTY), 202-272-2022 (fax), [cultural-diversity@ncd.gov](mailto:cultural-diversity@ncd.gov) (e-mail).

#### Cultural Diversity Advisory

**Committee Mission:** The purpose of NCD's Cultural Diversity Advisory Committee is to provide advice and recommendations to NCD on issues affecting people with disabilities from culturally diverse backgrounds. Specifically, the committee will help identify issues, expand outreach, infuse participation, and elevate the voices of underserved and unserved segments of this nation's population that will help NCD develop federal policy that will address the needs and advance the civil and human rights of people from diverse cultures.

**Accommodations:** People needing reasonable accommodations should notify NCD at least two weeks before these meetings.

Dated: October 16, 2007.

**Michael C. Collins,**

*Executive Director.*

[FR Doc. E7-21034 Filed 10-24-07; 8:45 am]

**BILLING CODE 6820-MA-P**

## NATIONAL COUNCIL ON DISABILITY

### Youth Advisory Committee Meetings (Teleconferences)

**AGENCY:** National Council on Disability (NCD).

Pursuant to the Federal Advisory Committee Act, P. L. 92-463, NCD gives notice that the Youth Advisory Committee will hold meetings on the dates and times noted below. The Committee will meet by conference call. All meetings are open to the public.

#### DATES AND TIMES:

Thursday, November 15, 2007, 4 p.m. EST.

Thursday, January 17, 2008, 4 p.m. EST.

Thursday, April 17, 2008, 4 p.m. EDT.

**Place:** National Council on Disability, 1331 F Street, NW., Suite 850, Washington, DC

**Status:** All parts of these conference calls will be open to the public. People interested in observing on conference calls should contact the appropriate staff member listed below. Due to limited resources, only a few telephone lines will be available for each conference call.

**Agenda:** Roll call, announcements, reports, new business, adjournment. A detailed agenda will be posted 10 days before each meeting at <http://www.ncd.gov/newsroom/advisory/youth/youth.htm>.

#### FOR FURTHER INFORMATION CONTACT:

Gerrie Drake Hawkins, Ph.D., Senior Program Analyst, National Council on Disability, 1331 F Street, NW., Suite 850, Washington, DC 20004; 202-272-2004 (voice), 202-272-2074 (TTY), 202-272-2022 (fax), [youth@ncd.gov](mailto:youth@ncd.gov) (e-mail).

**Accommodations:** People needing reasonable accommodations should notify NCD at least two weeks before this meeting.

#### Youth Advisory Committee Mission:

The purpose of NCD's Youth Advisory Committee is to provide input into NCD activities consistent with the values and goals of the Americans with Disabilities Act.

Dated: October 16, 2007.

**Michael C. Collins,**

*Executive Director.*

[FR Doc. E7-21033 Filed 10-24-07; 8:45 am]

**BILLING CODE 6820-MA-P**

## NUCLEAR REGULATORY COMMISSION

### Final Regulatory Guides: Issuance, Availability

**AGENCY:** Nuclear Regulatory Commission.

**ACTION:** Issuance, Availability of Regulatory Guides 1.84, 1.147, and 1.193.

#### FOR FURTHER INFORMATION CONTACT:

Wallace E. Norris, U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001, telephone (301) 415-6796 or e-mail to [WEN@nrc.gov](mailto:WEN@nrc.gov).

**SUPPLEMENTARY INFORMATION:** The U.S. Nuclear Regulatory Commission (NRC) has issued revisions to existing guides in the agency's "Regulatory Guide" series. This series was developed to describe and make available to the public information such as methods that are acceptable to the NRC staff for implementing specific parts of the agency's regulations, techniques that the staff uses in evaluating specific problems or postulated accidents, and data that the staff needs in its review of applications for permits and licenses.

Revision 34 of Regulatory Guide 1.84, "Design, Fabrication, and Materials Code Case Acceptability, ASME Section III," lists all Section III Code Cases that the NRC has approved for use. For Revision 34 of the guide, the NRC staff reviewed the Section III Code Cases listed in Supplements 7-12 to the 2001 Edition of the American Society of Mechanical Engineers (ASME) Boiler and Pressure Vessel (BPV) Code and Supplement 1 to the 2004 Edition. Appendix A to this guide lists the supplements reviewed, the applicable edition, and the date on which each supplement was approved by the ASME Board on Nuclear Codes and Standards. Appendix B is a list of the Section III Code Cases addressed in the seven supplements. Finally, Appendix C is a current list of all Section III Code Cases.

In October 2006, the NRC published a draft of this guide as Draft Regulatory Guide (DG)-1133. The public comment period closed on January 2, 2007. The staff's responses to the public comments are located in the NRC's Agencywide Documents Access and Management System (ADAMS), Accession Number ML072080205.

For Revision 15 of Regulatory Guide 1.147, "Inservice Inspection Code Case Acceptability, ASME Section XI, Division I," the NRC staff reviewed the Section XI Code Cases listed in Supplements 7-12 to the 2001 Edition, and Supplement 1 to the 2004 Edition of the ASME BPV Code. Appendix A to